---
title: "Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload | AKTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284217097.md"
description: "Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload | AKTX Stock News"
datetime: "2026-04-27T04:35:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284217097.md)
  - [en](https://longbridge.com/en/news/284217097.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284217097.md)
---

# Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload | AKTX Stock News

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload | AKTX Stock News

### Related Stocks

- [AKTX.US](https://longbridge.com/en/quote/AKTX.US.md)

## Related News & Research

- [Akari Therapeutics Delays Quarterly SEC Filing](https://longbridge.com/en/news/286828350.md)
- [Akari Therapeutics Plc 1Q 2026: Net income $(14.5M), EPS $(0.00) — 10-Q Summary](https://longbridge.com/en/news/286968149.md)
- [Atrium Therapeutics Reports First Quarter 2026 Financial Results | RNA Stock News](https://longbridge.com/en/news/286465472.md)
- [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md)
- [Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase | AKTX Stock News](https://longbridge.com/en/news/286776452.md)